Clinical trial
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated…
NCT00069745 · Agennix, Industry · Completed
Key facts
| NCT number | NCT00069745 |
|---|---|
| Title | Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen |
| Official title | A Multi-National Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen |
| Lead sponsor | Agennix, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Hormone Refractory Prostate Cancer |
| Intervention type | Drug |
| Interventions | Satraplatin, Prednisone |
| Start date | Sep 1, 2003 |
| Primary completion | Jan 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Oct 6, 2003 |
| Last update posted | Aug 7, 2012 |
| Countries | Argentina, Belgium, Croatia, France, Germany, Hungary, Israel, Italy, Netherlands, Peru, Poland, Russia and 3 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: